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ABSTRACT 
Very rarely Stevens Johnson Syndrome develops following drug therapy particularly Lithium 
and Valproate. Worldwide, the reports regarding Lithium and Valproate induced Stevens Johnson 
Syndrome are very few. Here, we present two cases of Stevens Johnson Syndrome following treatment 
with Lithium and Valproate for Mood Disorder. 
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Stevens Johnson syndrome begins with a 
non specific prodrome of one to fourteen-days in 
at least half of the patients; fever, malaise, 
headache, rhinitis, cough, sore throat, chest pain, 
vomiting, myalgia and arthralgia. Cutaneous 
lesions in Stevens Johnson Syndrome generally 
consist initially of erythematous macules that 
rapidly and variably develop central necrosis to 
form vesicles, bullae and areas of denudation on 
the face, trunk and extremities. The skin lesions 
typically are more widespread than in extremities 
and are accompanied by involvement of two or 
more mucosal surfaces, namely eyes, oral cavity, 
upper airway or esophagus, gastrointestinal tract 
or anogenital mucosa. A burning sensation, 
edema and erythema of the lips and the buccal 
mucosa are often the presenting signs, followed 
by development of bullae, ulceration and 
haemorrhagic crusting. Pain from the mucosal 
ulceration is often severe and skin tenderness is 
minimal to absent. The body surfaces affected 
are <10% to >30% or more. Internal organs 
involvement is rare in Stevens Johnson Syndrome. 
But some cases affect respiration and G.I.tract. 
Tracheal and bronchial symptoms may occur. 
Less commonly ideal involvements, hepatitis, 
colonic perforations have been reported. 
Long and short-term treatment with Lithium 
with periodic checkup is an effective way to reduce 
the frequency, severity, and duration of manic 
and depressive episodes in patients with bipolar 
disorder Valproate is widely used in the short-
term treatment of the manic phase of bipolar I 
disorder and in the prophylactic treatment of 
patients with recurrent manic and depressive 
episodes. 
Case I: A 30 year old male reported at the O.P.D. 
of the Dept. of Psychiatry for extensive skin 
rashes and few vesicles present over face, neck, 
body, oral and genital mucous membranes for 5 
days following intake of Lithium (1050 mg in divided 
doses) as advised by the psychiatrist of C.I.P., 
Ranchi. He was advised to discontinue Lithium 
and to attend the O.P.D. of Skin and V.D. 
Department immediately, when he was suspected 
as a case of Stevens Johnson Syndrome in the 
Dept of Psychiatry Subsequently the patient was 
taken over by the skin and VD department 
confirming the diagnosis of Stevens Johnson 
Syndrome, and treated with injection of 
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Dexamethasone, Roxithromicin, topical antibiotic, 
antihistaminics, topical steroids, and mouth wash. 
During the course of treatment, the patient was 
referred for psychiatric consultation for 
management problem. On bedside referral, the 
patient was irritable and was advised to continue 
clonazepam 4 mg per day in divided doses. Finally, 
the patient was cured and discharged. 
On detail evaluation, the patient was 
admitted at C.I.P.Ranchi for acute mania 
(excessive speech, decreased sleep, 
distractibility, increased motor activity, elevated 
mood, inflated self-esteem, gross impairment of 
social and occupational functioning) and 
maintained only on Lithium during discharge. He 
had 2 similar episodes in the past, 1993 and 1998, 
treated at the Dept. of Psychiatry and completely 
remitted. The Interepisodic period was symptom 
free. 
Subsequently it was reported by his key 
relative that he expired of heat exhaustion as per 
the opinion of local physician. 
Case 2: A 39 year old Hindu male reported at 
the clinic of consultant psychiatrist for bipolar 
disorder, currently depressed (sad mood, 
anhedonia, early morning awakening, irritability, 
loss of app.etite) of 2-1/2 year duration and was 
treated with Valproate,600-mg per day ; 
clonazepam, 1mg per day; alprazolam, 0.5 mg 
per day and diazepam, 10 mg at night. After 4 
days, he again reported at the clinic for extensive 
rashes with vesicles over his face, neck, thorax, 
oral and ocular involvement. Valproate was 
withdrawn immediately and he was advised to 
consult the dermatologist and to continue the 
rest of the medicines. The dermatologist advised 
injection dexamethasone, topical antibiotics, 
antihistaminics, topical steroids, and 
conservative management was done, on which 
the patient recovered completely and he had a 
symptom free maintenance. 
On detail evaluation, it was revealed that 
the patient had reported at O.P.D. of the Dept. 
of Psychiatry for features of bipolar disorder, 
acute mania (talkative, impaired sleep, elated 
mood, involvement in pleasurable activities such 
as singing, increased motor activity, disturbed 
social and occupational functioning) from 1998. 
There was family history of bipolar disorder in 
maternal grandfather. He was admitted once and 
subsequently maintained only on conventional 
anti-psychotics until depressive phase. 
DISCUSSION 
In spite of the fact that Valproate and 
Lithium have been approved as mood stabilizers 
by the U.S.FDA. and are being extensively used 
throughout the World in clinical practice with 
definite benefits, periodic evaluation of cases, 
serum lithium monitoring is essential to avoid 
hypersensitivity reactions and toxicity, which will 
be beneficial for a better maintenance of the 
patients with an early diagnosis of the condition, 
if at all the patient develops Stevens Johnson 
Syndrome during the course of treatment. 
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